Get the Stockscreener App
123.39
0.03%
0.04
After Hours:
123.39
Nuvalent Inc stock is traded at $123.39, with a volume of 2.21M.
It is up +0.03% in the last 24 hours and up +20.62% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$123.35
Open:
$123.41
24h Volume:
2.21M
Relative Volume:
1.26
Market Cap:
$9.76B
Revenue:
-
Net Income/Loss:
$-450.07M
P/E Ratio:
-20.37
EPS:
-6.0583
Net Cash Flow:
$-312.79M
1W Performance:
+0.11%
1M Performance:
+20.62%
6M Performance:
+20.23%
1Y Performance:
+61.67%
1-Day Range:
$123.28
$123.47
1-Week Range:
$123.15
$123.57
52-Week Range:
$71.13
$123.62
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
123.39 | 9.76B | 0 | -450.07M | -312.79M | -6.0583 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Wells Fargo | Overweight |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-12-25 | Initiated | Canaccord Genuity | Buy |
| Oct-16-25 | Resumed | Stifel | Buy |
| Oct-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal - Streetwise Reports
AASTOCKS Financial NewsNuvalent, Inc. (NUVL) - AASTOCKS.com
GSK agrees to acquire Nuvalent, Inc. - Pennsylvania Business Report -
Halper Sadeh LLC is Investigating Whether DAN, NUVL, SUNE, TMHC are Obtaining Fair Deals for their Shareholders - GlobeNewswire
GSK in talks to buy Nuvalent for more than $9 billion: FT - MSN
GSK To Acquire Nuvalent In Largest Deal In Over A Decade – Merger Arbitrage Mondays (NYSE:GSK) - Seeking Alpha
GSK buys Nuvalent for $10.6 billion in major cancer push - MSN
Nuvalent, Inc. (NUVL) Stock Analysis: Assessing the 3.96% Potential Upside Amidst Biotech Innovation - DirectorsTalk Interviews
Herbert Smith Freehills Kramer advises on the financing for GSK plc's US$10.6 billion acquisition of Nuvalent Inc. - Legal Desire Media and Insights
NUVL stock surges 39% premarket – why is GSK buying this Boston-based oncology company? - MSN
GSK to Acquire Nuvalent for $10.6 Billion - GuruFocus
The week in pharma: action, reaction and insight – week to June 12, 2026 - The Pharma Letter
Weekend Morning Brew: SpaceX IPO Soars; GSK Acquires Nuvalent - GuruFocus
Patent cliff predators: GSK acquires Nuvalent for $10.6 billion - MSN
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK - MSN
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders? - TradingView
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $124 to $126 - Moomoo
Nuvalent (NUVL) CDO sells 20,000 shares, exercises options - Stock Titan
Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors - Seeking Alpha
GSK To Acquire Nuvalent for $10.6 Bn - DCAT Value Chain Insights
GSK to acquire Nuvalent for $10.6bn ahead of patent cliff - EMJ
Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion - MSN
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion - Investing.com
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion - MarketBeat
Slaughters, Davis Polk, Ropes line up on GSK’s $10.6bn biotech buy - Non-Billable
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal - TradingView
GSK Makes $10.6 Billion Oncology Bet With Nuvalent Acquisition to Accelerate Cancer Expansion (GSK) - Yahoo Finance UK
GSK Strikes $10.6 Billion Deal for Nuvalent in One of Pharma's Biggest Oncology Acquisitions of 2026 - CHEManager
GSK Acquires Nuvalent To Maximise Cancer Treatments - Healthcare Digital
GSK Announces Record $10.6 Billion Acquisition of Nuvalent to Rebuild Oncology Portfolio - IndexBox
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal By Reuters - Investing.com
Investigation launched into Nuvalent's $10.6B deal with GSK over possible board breaches and unfair terms - Pluang
GSK to acquire Nuvalent for $10.6 billion in cash deal - scanx.trade
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK - BioSpace
GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares - MSN
GSK makes $10.6B move for Nuvalent to boost cancer pipeline - MSN
GSK strikes deal to buy lung cancer drugmaker Nuvalent for $10.6bn - MSN
GSK to buy Nuvalent for $10.6 billion in oncology push - MSN
GSK plc to pursue cash tender offer for Nuvalent (NASDAQ: NUVL) - Stock Titan
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
GSK to Acquire Nuvalent for $10.6B, Boosting Cancer Pipeline with Precision NSCLC Treatments - Genetic Engineering and Biotechnology News
GSK’s US$10.6b Nuvalent Purchase Recasts Oncology And Future Revenue Mix - simplywall.st
GSK Enters Agreement to Acquire Nuvalent Inc June 10, 2026 - James Sharp & Co.
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc.NUVL - Business Wire
GSK advances oncology efforts with $10.6bn Nuvalent acquisition - European Pharmaceutical Review
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
GSK Acquires Nuvalent for $10.6 Billion in Lung Cancer Push - PharmTech.com
GSK to Acquire U.S. Biotech Firm Nuvalent for $10.6bn in Largest Pharma Deal in a Decade - Tekedia
Bernstein reiterates Nuvalent stock rating on GSK acquisition - Investing.com
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
GSK's $10.6B Nuvalent buy gains analyst backing for lung cancer growth amid HIV patent worries - Pluang
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Jun 09 '26 |
Sale |
122.81 |
20,000 |
2,456,200 |
58,117 |
| Porter James Richard | President and CEO |
Jun 08 '26 |
Option Exercise |
18.93 |
30,000 |
567,900 |
354,879 |
| Porter James Richard | President and CEO |
Jun 08 '26 |
Sale |
88.53 |
30,000 |
2,656,004 |
324,879 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):